Idiopathic pulmonary fibrosis will increase the risk of lung cancer

Chinese Medical Journal

Volumn 127, Issue 17, 2014, Pages 3142-3149

  Li, Jun Yao ^a   Yang, Ming ^b   Li, Ping ^a   Su, Zhen Zhong ^a   Gao, Peng ^a   Zhang, Jie ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Idiopathic pulmonary fibrosis; Lung cancer; Prevalence; Risk factors

Indexed keywords

BETA CATENIN; CYCLIN D; CYCLOOXYGENASE 2; K RAS PROTEIN; MATRILYSIN; MICRORNA; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

AGE; ANATOMY; ARTICLE; CANCER RISK; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; EPIGENETICS; EPITHELIUM; FIBROSING ALVEOLITIS; GENDER; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG FIBROBLAST; LUNG SQUAMOUS CELL CARCINOMA; MORBIDITY; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PREVALENCE; RADIOGRAPHY; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING; TISSUE INJURY; COMPLICATION; FEMALE; GENETICS; IDIOPATHIC PULMONARY FIBROSIS; LUNG NEOPLASMS; MALE; SEX DIFFERENCE;

AGE FACTORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG NEOPLASMS; MALE; RISK FACTORS; SEX FACTORS;

EID: 84906967112     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20141346     Document Type: Article

References (76)

1. King Jr TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
3. Lipchik RJ. ACP Journal Club. Review: Current drug treatments do not reduce mortality in idiopathic pulmonary fibrosis. Ann Intern Med 2011; 154: JC6-JC8.
4. Song DH, Choi IH, Ha SY, Han KM, Lee JJ, Hong ME, et al. Usual interstitial pneumonia with lung cancer: clinicopathological analysis of 43 cases. Korean J Pathol 2014; 48: 10-16.
5. Spain D. The association of terminal bronchiolar carcinoma with chronic interstitial inflammation and fibrosis of the lungs. Am Rev Tuberc 1957; 76: 559-566.
6. Stack BH, Grant IW, Irvine WJ, Moffat MA. Idiopathic diffuse interstitial lung disease. A review of 42 cases. Am Rev Respir Dis 1965; 92: 939-948.
7. Meyer EC, Liebow AA. Relationship of interstitial pneumonia honeycombing and atypical epithelial proliferation to cancer of the lung. Cancer 1965; 18: 322-351.
8. Haddad R, Massaro D. Idiopathic diffuse interstitial pulmonary fibrosis (fibrosing alveolitis), atypical epithelial proliferation and lung cancer. Am J Med 1968; 45: 211-219.
9. Fraire AE, Greenberg SD. Carcinoma and diffuse interstitial fibrosis of lung. Cancer 1973; 31: 1078-1086.
10. Turner-Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35: 496-499.
11. Kawai T, Yakumaru K, Suzuki M, Kageyama K. Diffuse interstitial pulmonary fibrosis and lung cancer. Acta Pathol Jpn 1987; 37: 11-19.
12. Nagai A, Chiyotani A, Nakadate T, Konno K. Lung cancer in patients with idiopathic pulmonary fibrosis. Tohoku J Exp Med 1992; 167: 231-237.
13. Matsushita H, Tanaka S, Saiki Y, Hara M, Nakata K, Tanimura S, et al. Iung cancer associated with usual interstitial pneumonia. Pathol Int 1995; 45: 925-932.
14. Wells C, Mannino DM. Pulmonary fibrosis and lung cancer in the United States: analysis of the multiple cause of death mortality data, 1979 through 1991. South Med J 1996; 89: 505-510.
15. Hironaka M, Fukayama M. Pulmonary fibrosis and lung carcinoma: a comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol Int 1999; 49: 1060-1066.
16. Qunn L, Takemura T, Ikushima S, Ando T, Yanagawa T, Akiyama O, et al. Hyperplastic epithelial foci in honeycomb lesions in idiopathic pulmonary fibrosis. Virchows Arch 2002; 441: 271-278.
17. Araki T, Katsura H, Sawabe M, Kida K. A clinical study of idiopathic pulmonary fibrosis based on autopsy studies in elderly patients. Intern Med 2003; 42: 483-489.
18. Rudd RM, Prescott RJ, Chalmers JC, Johnston ID. British thoracic society study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 2007; 62: 62-66.
19. Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 2009; 14: 723-728.
20. Harris JM, Johnston ID, Rudd R, Taylor AJ, Cullinan P. Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax 2010; 65: 70-76.
21. Bouros D, Hatzakis K, Labrakis H, Zeibecoglou K. Association of malignancy with diseases causing interstitial pulmonary changes. Chest 2002; 121: 1278-1289.
22. Samet JM. Does idiopathic pulmonary fibrosis increase lung cancer risk? Am J Respir Crit Care Med 2000; 161: 1-2.
23. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161: 5-8.
24. Ogura T, Kondo A, Sato A, Ando M, Tamura M. Incidence and clinical features of lung cancer in patients with idiopathic interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi 1997; 35: 294-299.
25. Ma Y, Seneviratne CK, Koss M. Idiopathic pulmonary fibrosis and malignancy. Curr Opin Pulm Med 2001; 7: 278-282.
26. Aubry MC, Myers JL, Douglas WW, Tazelaar HD, Washington Stephens TL, Hartman TE, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc 2002; 77: 763-770.
27. Shimizu H. Pathological study of lung cancer associated with idiopathic interstitial pneumonia--with special reference to relationship between the primary site of lung cancer and honeycombing. Nihon Kyobu Shikkan Gakkai Zasshi 1985; 23: 873-881.
28. Kawasaki H, Nagai K, Yokose T, Yoshida J, Nishimura M, Takahashi K, et al. Clinicopathological characteristics of surgically resected lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol 2001; 76: 53-57.
29. Kuhara H, Wakabayashi T, Kishimoto H, Morishita M, Suzuki T, Yamamoto M. Synchronous bilateral double primary lung cancer associated with diffuse interstitial fibrosing pneumonitis (DIFP). Acta Pathol Jpn 1984; 34: 617-629.
30. Kusajima K, Murata Y, Ohshi F, Shimoide H, Kimura B, Sugita H, et al. Characteristics of chronic interstitial pneumonia seen in the lung operated for lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi 1992; 30: 1673-1681.
31. Mizushima Y, Kobayashi M. Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. Chest 1995; 108: 1272-1277.
32. Rohwedder JJ, Weatherbee L. Multiple primary bronchogenic carcinoma with a review of the literature. Am Rev Respir Dis 1974; 109: 435-445.
33. Valeyre D. Towards a better diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2011; 20: 108-113.
34. Yoshida R, Arakawa H, Kaji Y. Lung cancer in chronic interstitial pneumonia: early manifestation from serial CT observations. AJR Am J Roentgenol 2012; 199: 85-90.
35. Lee HJ, Im JG, Ahn JM, Yeon KM. Lung cancer in patients with idiopathic pulmonary fibrosis: CT findings. J Comput Assist Tomogr 1996; 20: 979-982.
36. Fukayama M, Ibuka T, Hayashi Y, Ooba T, Koike M, Mizutani S. Epstein-Barr virus in pyothorax-associated pleural lymphoma. Am J Pathol 1993; 143: 1044-1049.
37. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-1006.
38. Wu MS, Shun CT, Lee WC, Chen CJ, Wang HP, Lee WJ, et al. Gastric cancer risk in relation to Helicobacter pylori infection and subtypes of intestinal metaplasia. Br J Cancer 1998; 78: 125-128.
39. Todd NW, Scheraga RG, Galvin JR, Iacono AT, Britt EJ, Luzina IG, et al. Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis. J Inflamm Res 2013; 6: 63-70.
40. Wang ZL, Fan ZQ, Jiang HD, Qu JM. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis 2013; 34: 638-646.
41. Konigshoff M. Lung cancer in pulmonary fibrosis: tales of epithelial cell plasticity. Respiration 2011; 81: 353-358.
42. Chilosi M, Poletti V, Zamò A, Lestani M, Montagna L, Piccoli P, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162: 1495-1502.
43. Honda E, Park AM, Yoshida K, Tabuchi M, Munakata H. Myofibroblasts: biochemical and proteomic approaches to fibrosis. Tohoku J Exp Med 2013; 230: 67-73.
44. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 2006; 103: 13180-13185.
45. De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 2008; 130: 481-494.
46. Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol 2009; 86: 1111-1118.
47. Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004; 64: 8492-8495.
48. Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004; 48: 509-517.
49. Bhowmick NA, Moses HL. Tumor–stroma interactions. Curr Opin Genet Dev 2005; 15: 97-101.
50. Niki T, Kohno T, Iba S, Moriya Y, Takahashi Y, Saito M, et al. Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. Am J Pathol 2002; 160: 1129-1141.
51. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006; 5: 2592-2601.
52. Chilosi M, Zamò A, Doglioni C, Reghellin D, Lestani M, Montagna L, et al. Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir Res 2006; 7: 95.
53. Mori R, Power KT, Wang CM, Martin P, Becker DL. Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration. J Cell Sci 2006; 119: 5193-5203.
54. Trovato-Salinaro A, Trovato-Salinaro E, Failla M, Mastruzzo C, Tomaselli V, Gili E, et al. Altered intercellular communication in lung fibroblast cultures from patients with idiopathic pulmonary fibrosis. Respir Res 2006; 7: 122.
55. Cesen-Cummings K, Fernstrom MJ, Malkinson AM, Ruch RJ. Frequent reduction of gap junctional intercellular communication and connexin43 expression in human and mouse lung carcinoma cells. Carcinogenesis 1998; 19: 61-67.
56. Avanzo JL, Mesnil M, Hernandez-Blazquez FJ, Mackowiak II, Mori CM, da Silva TC, et al. Increased susceptibility to urethane-induced lung tumors in mice with decreased expression of connexin43. Carcinogenesis 2004; 25: 1973-1982.
57. Zhang ZQ, Zhang W, Wang NQ, Bani-Yaghoub M, Lin ZX, Naus CC. Suppression of tumorigenicity of human lung carcinoma cells after transfection with connexin43. Carcinogenesis 1998; 19: 1889-1894.
58. Yoshimura A, Kudoh S. Idiopathic pulmonary fibrosis and lung cancer. Gan To Kagaku Ryoho 2003; 30: 215-222.
59. Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, et al. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins. Tumori 2007; 93: 473-477.
60. Takahashi T, Munakata M, Ohtsuka Y, Nisihara H, Nasuhara Y, Kamachi-Satoh A, et al. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis. Cancer 2002; 95: 624-633.
61. Uematsu K, Yoshimura A, Gemma A, Mochimaru H, Hosoya Y, Kunugi S, et al. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res 2001; 61: 8527-8533.
62. Uematsu K, Yoshimura A, Gemma A, Hosoya Y, Kudoh S. Fluorescent in situ hybridization (FISH) of the FHIT gene in idiopathic pulmonary fibrosis (IPF) lesions. J Nippon Med Sch 2003; 70: 298-299.
63. Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 2010; 5: e10680.
64. Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP, et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008; 39: 610-618.
65. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011; 157: 191-199.
66. Ho CS, Yap SH, Phuah NN, In LL, Hasima N. MicroRNAs associated with tumour migration, invasion and angiogenic properties in A549 and SK-Lu1 human lung adenocarcinoma cells. Lung Cancer 2014; 83: 154-162.
67. Pandit KV, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, Gibson KF, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182: 220-229.
68. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207: 1589-1597.
69. Yang S, Banerjee S, de Freitas A, Sanders YY, Ding Q, Matalon S, et al. Participation of miR-200 in pulmonary fibrosis. Am J Pathol 2012; 180: 484-493.
70. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009; 84: 52-59.
71. Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer letters 2005; 222: 1-10.
72. Bowley E, O’Gorman DB, Gan BS. β-catenin signaling in fibroproliferative disease. J Surg Res 2007; 138: 141-150.
73. Al-Saad S, Donnem T, Al-Shibli K, Persson M, Bremnes RM, Busund LT. Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res 2009; 29: 4175-4183.
74. Cigna N, Farrokhi Moshai E, Brayer S, Marchal-Somme J, Wémeau-Stervinou L, Fabre A, et al. The hedgehog system machinery controls transforming growth factor-beta-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis. Am J Pathol 2012; 181: 2126-2137.
75. Bolanos AL, Milla CM, Lira JC, Ramírez R, Checa M, Barrera L, et al. Role of Sonic Hedgehog in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 303: L978-L990.
76. Bermudez O, Hennen E, Koch I, Lindner M, Eickelberg O. Gli1 mediates lung cancer cell proliferation and Sonic Hedgehog-dependent mesenchymal cell activation. PLoS One 2013; 8: e63226.